“I’ve had the pleasure of working closely with Aaron and can say without hesitation that he brings seasoned intelligence, sound ethical judgment, and genuine kindness to every interaction. In an industry where trust and insight are paramount, Aaron stands out as both a sharp investor and a thoughtful colleague. I’d work with him again in a heartbeat. ”
About
Senior Investment Professional | Private Equity, Corporate Development
With deep…
With deep…
Experience & Education
Organizations
-
ImageArb
-
- PresentImageArb helps investment managers and financial service firms put their best foot forward by enabling you to clearly communicate how your approach or strategy will generate returns and add value.
Recommendations received
6 people have recommended Aaron
Join now to viewOther similar profiles
Explore more posts
-
Hunter Walk
Clarity Pediatrics just posted two high-impact, career-accelerating roles to propel the next chapter in pediatric chronic care access and delivery. Director, Provider Growth Marketing (focus on pediatricians) - reporting to CMO Laura Artigas (SF or virtual) Growth GM, initial focus on TX market and then beyond - reporting to Head of GTM Jake Powell (Dallas, Houston or Austin) https://lnkd.in/gqvQDtHu
5 Comments -
Lisa Piercey
💡"Focusing on women-specific outcomes offers a real opportunity to create alpha by investing where competitors have not spent much time or capital, creating room for differentiation and early leadership." Kudos to Millie Nelson and BioXconomy for drawing attention to the positive impact of investing in women's health!
2 Comments -
Anna Kari
The Great Recalibration of Healthcare: Why Margin First Now Leads Growth Healthcare investing is undergoing a major recalibration. Investors are shifting focus from growth-at-all-costs to sustainable margins, commercial execution, operational efficiency, and clear paths to profitability in an increasingly selective market. Key Takeaways from: Ross Morton (Nodenza): the old models are quickly becoming broken." Opportunity remains strong in deep tech and cross-border launches. Nola E. Masterson (Portfolia.co): patients are now driving the market, especially in women's health, digital care, and AI-supported tools. IPO exits are largely closed, making M&A the main path to liquidity. Nirmal Patel (Hawk Family Office): AI is helping companies do more with leaner teams, strengthening unit economics earlier. Ambuj Mathur (Indite Ventures): investing can't rely on hoping for a higher exit valuation. AI could also cut drug development timelines significantly. Shaan Gandhi (Pfizer): commercial plans are under far more scrutiny. Go-to-market strategy and reimbursement need to be part of the investment case from day one. Nicholas Watkins (White Cloud Capital): capital still matters, but companies can't be starved of resources either. Bottom line: The great recalibration of healthcare is not the end of ambition. It is the start of a more mature investment cycle. The companies most likely to succeed will be those that combine strong science, patient relevance, reimbursement clarity, commercial discipline and credible margins. Growth still matters. But in this new healthcare market, growth must now prove that it can pay for itself. Full summary here: https://lnkd.in/e6BR3rQG #HealthcareInnovation #ImpactInvesting #VentureCapital #PrivateEquity #HealthTech
1 Comment
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content